Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belnacasan in mild to moderate COVID-19
NCT05164120Phase 2Completed
- Sponsor
- MedStar Health
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belnacasan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by MedStar Health. Primary endpoint: Safety and Tolerability of Belnacasan at 60 days. Started Dec 2021; status: completed.
02
Drugs
belnacasan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05164120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164120.